Valuation: ME Therapeutics Holdings Inc.

Market Cap 7.6Cr 5.35Cr 4.8Cr 4.42Cr 4.01Cr 501.42Cr 7.81Cr 53Cr 21Cr 268.65Cr 20Cr 20Cr 849.26Cr P/E 2024
-51.7x
P/E 2025 -93.2x
Enterprise Value 7.46Cr 5.25Cr 4.71Cr 4.34Cr 3.94Cr 492.64Cr 7.67Cr 52Cr 21Cr 263.94Cr 20Cr 19Cr 834.38Cr EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
44.63%
Yield 2024 *
-
Yield 2025 -
1 week-4.55%
Current month-4.55%
1 month-62.50%
3 months-58.00%
6 months-64.41%
Current year-73.75%
1 week 1.05
Extreme 1.05
1.05
1 month 0.95
Extreme 0.95
1.8
Current year 0.79
Extreme 0.79
4.1
1 year 0.79
Extreme 0.79
4.1
3 years 0.05
Extreme 0.05
11
5 years 0.05
Extreme 0.05
11
10 years 0.05
Extreme 0.05
11
Manager TitleAgeSince
Chief Executive Officer 46 09/03/2023
Director of Finance/CFO 44 09/03/2023
Corporate Officer/Principal - 25/10/2024
Director TitleAgeSince
Director/Board Member 60 09/03/2023
Director/Board Member 46 09/03/2023
Director/Board Member 59 09/03/2023
Date Insider Type Main position Quantity % Market Cap. Importance
16/07/26 Option

Director

2,94,118 0.9788%
16/07/26 Sell

Director

2,94,118 0.9788%
16/07/26 Option

Chief Financial Officer

1,25,000 0.4160%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-4.55%-73.75%-80.91% 2.25Cr
+0.01%+11.10%+60.83%+70.43% 6.83TCr
+0.69%+6.77%+14.11%+89.13% 6.03TCr
+0.09%-0.03%+19.65%+97.08% 5.59TCr
+1.60%+19.44%+28.80%+112.95% 4.84TCr
-1.32%+4.78%+29.15%+40.40% 4.53TCr
-3.54%-0.60%+207.76%+879.50% 4.18TCr
-3.33%+6.90%+22.78%+48.07% 3.45TCr
-1.40%-1.17%+84.26%+56.60% 3.38TCr
-1.49%+1.16%+47.05%+0.16% 2.6TCr
Average -0.88%+4.40%+44.06%+131.34% 4TCr
Weighted average by Cap. -0.69%+5.25%+53.95%+152.58%

Financials

2024 2025
Net sales - -
Net income -12.95L -9L -8L -8L -7L -8.54Cr -13.31L -90.19L -35.93L -4.58Cr -34.2L -33.48L -14Cr -11.93L -8L -8L -7L -6L -7.88Cr -12.27L -83.12L -33.12L -4.22Cr -31.52L -30.85L -13Cr
Net Debt -14.97L -10.54L -9L -9L -8L -9.88Cr -15.39L -1.04Cr -41.54L -5.29Cr -39.54L -38.7L -17Cr -13.31L -9L -8L -8L -7L -8.79Cr -13.68L -92.74L -36.95L -4.71Cr -35.17L -34.42L -15Cr
Projected Income Statement - Annual - ME Therapeutics Holdings Inc.
Logo ME Therapeutics Holdings Inc.
ME Therapeutics Holdings Inc. is a preclinical stage biotechnology company involved in the discovery and development of novel immune oncology therapeutics targeting immune suppression in cancer. The Company’s focus is on overcoming the suppressive effects of a class of immune cells called myeloid cells to enhance anti-cancer immunity. The Company’s lead candidate is a novel high affinity antibody drug that targets a key protein involved in the generation of suppressive myeloid cells. In addition to its antibody drug candidate program, the Company is also developing a novel small molecule prodrug candidate designed to specifically target suppressive myeloid cells in the tumor environment. The Company has initiated design and testing of two new mRNA-based cancer therapeutic drug candidates.
Employees
-
Date Price Change Volume
05/26/05 CA$1.050 0.00% 1,000
  1. Stock Market
  2. Stocks
  3. METX Stock